Zealand Pharma Opens Cambridge Hub, Expands Biologics and Hybrid Modalities

Zealand Pharma's decision to anchor its primary U.S. research presence at 35 CambridgePark Drive signals a deliberate platform expansion beyond the peptide chemistry that has defined the company for over 25 years — and the shift into antibody-peptide conjugates and other hybrid modalities carries manufacturing complexity that will eventually reach CMC and process development teams.

The 53,600 RSF facility, first announced in March 2026, was formally inaugurated on September 30 with a ribbon-cutting attended by Cambridge Mayor Sumbul Siddiqui, the Danish Ambassador to the United States, and MassBio President Kendalle Burlin O'Connell. The site now functions as the company's principal U.S. address and operates in parallel with its Copenhagen research base, extending what Zealand describes as its Metabolic Frontier 2030 strategy targeting leadership in obesity and metabolic health.

From a research operations standpoint, the hub is structured around automation and advanced computational modeling — tools the company's Chief Scientific Officer Utpal Singh cited as central to compressing cycle time from candidate identification to IND-enabling studies. For QA and regulatory leads tracking how AI-assisted design intersects with ICH Q10 pharmaceutical quality system expectations, the integration of machine learning into early-stage candidate selection is an area regulators have begun to scrutinize in pre-submission interactions, even before a molecule reaches formal process validation.

The platform expansion into biologics introduces a materially different analytical and sterility assurance burden relative to synthetic peptide manufacturing. Antibody-peptide conjugates, for instance, require conjugation process controls, linker stability characterization, and aggregation monitoring that fall outside conventional small-molecule or peptide GMP frameworks. As Zealand scales candidates from this new modality through development, CMC strategy and technology transfer planning will need to account for the added complexity early — particularly given the FDA's increasing emphasis on process understanding at the 21 CFR Part 211 stage.

Zealand is actively recruiting scientific staff at the Cambridge site, with further headcount growth anticipated, and has joined the Cambridge Chamber of Commerce. The company's pipeline already includes more than ten clinical-stage candidates invented in-house, providing a baseline of regulatory precedent the Cambridge team will build from as hybrid modality programs advance.

The pace at which antibody-peptide conjugate candidates move from the Cambridge automation platform into IND-enabling toxicology will serve as the first measurable indicator of whether the hub's compressed cycle-time model translates into regulatory-ready data packages.

Source: Zealand Pharma A/S via GlobeNewswire, October 1, 2026.